替吉奥一线治疗晚期胃癌的研究进展

S-1 as first-line treatment for advanced gastric cancer

晚期胃癌失去手术指征，化疗可延长患者的生存时间并提高生活质量，是主要治疗选择。但针对晚期胃癌目前仍无标准化疗方案。替吉奥自上市以来，在胃癌治疗中应用广泛，一些研究采用替吉奥与顺铂、紫杉类或伊立替康等细胞毒类药物联合一线治疗晚期胃癌，有效率在40％～50％，且安全性好。

Patients with advanced gastric cancer lose the surgical indications. Chemotherapy can improve the overall survival and quality of life, which is the main treatment option. But there is no standard chemotherapy regimen for the patients with advanced gastric cancer. Since its initial approval, S-1 is widely used in gastric cancer. Several studies were performed to explore combinations of S-1 with other cytotoxic drugs such as platinum, docetaxel, paclitaxel, and irinotecan. All these combinations were found to be promising, with response rates of around 40% -50% and relatively favorable safety profiles.